Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

AURORA, Colo., Nov. 8, 2023 /PRNewswire/ – Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California. Four of these studies have been accepted as oral presentations. 

Read the full article on PR Newswire.